In patients with melanoma and confirmed progression on a PD-1, lenvatinib plus pembrolizumab demonstrated clinically meaningful responses.
Rates of relapse-free and overall survival were high as well, exceeding 90%.
Patients were more likely to benefit from pembrolizumab if they had not previously received the drug.
Pembrolizumab bested high-dose interferon alfa-2b and high-dose ipilimumab.
As the Memorial Day weekend begins, many Americans are confused about the proper application of sunscreen and about its sun protection factor (SPF), the American Academy of Dermatology says.
The dermatoscopic characteristics of keratinizing skin cancer in patients prescribed antihypertives treatment is compared with that of non-users.
The link between treatment center academic affiliation and patient volume with long-term patient survival after Mohs micrographic surgery (MMS) was evaluated.
Lifileucel has produced responses lasting more than 2 years in patients with limited treatment options.
This is the first phase 3 study to validate LAG-3 inhibition as a therapeutic strategy in cancer, according to an investigator.
A comparison of outcomes for patients treated with high-dose methotrexate demonstrated the efficacy of a guideline established at a major cancer center.